Literature DB >> 1117072

Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

J B Ziegler, C A Alper, R S Rosen, P J Lachmann, L Sherington.   

Abstract

In a patient with lifelong increased susceptibility to infection and multiple abnormalities in complement-mediated functions, the infusion of normal plasma had been seen to produce a prolonged partial correction of serum abnormalities. It was subsequently shown that the patient was genetically deficient in the C3b inactivator and that immunochemical depletion of C3b inactivator from normal serum resulted in abnormalities similar to those found in the patient's serum, including alternative pathway C3 activation. Highly purified C3b inactivator was obtained from the euglobulin fraction of normal human serum, sterilized by filtration, and infused intravenously. Partial or complete correction of almost all the known serum abnormalities was obtained. C3b almost disappeared from the serum within 4-5 h, as did Factor C activity. Native C3, C5, and serum hemolytic activity rose to normal or near-normal levels over 4 days and were sustained for another week. Factor B, properdin, opsonic activity, and bactericidal activity reached a level at least two-five times that found before the infusion within 24 h and fell over the next 5 days. These observations prove the primary role of C3b inactivator deficiency in the patient's disease and demonstrate clearly the curcial role in vivo of C3b inactivator in modulating alternative pathway activity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1117072      PMCID: PMC301796          DOI: 10.1172/JCI107975

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Evaluation of opsonic and leukocyte function with a spectrophotometric test in patients with infection and with phagocytic disorders.

Authors:  T P Stossel
Journal:  Blood       Date:  1973-07       Impact factor: 22.113

2.  Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3).

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

3.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

4.  Further studies on the C3b inactivator or conglutinogen activating factor (KAF).

Authors:  P J Lachmann; P Nicol; W P Aston
Journal:  Immunochemistry       Date:  1973-10

5.  Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.

Authors:  W Vogt; L Dieminger; R Lynen; G Schmidt
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1974-02

6.  Deficiency of C3 inactivator in man.

Authors:  N Abramson; C A Alper; P J Lachmann; F S Rosen; J H Jandl
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

7.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

8.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

9.  Formation and function of a complex of the C3 proactivator with a protein from cobra venom.

Authors:  N R Cooper
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

10.  The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.

Authors:  C A Alper; I Goodkofsky; I H Lepow
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Editorial: Complement activation and disease.

Authors: 
Journal:  Br Med J       Date:  1976-02-21

3.  Properdin homeostasis requires turnover of the alternative complement pathway.

Authors:  Xiaobo Wu; Thomas Q Xu; John P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

4.  Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family.

Authors:  A S Grumach; M F Leitão; V G Arruk; M Kirschfink; A Condino-Neto
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Complement-activating ability of leucocytes from patients with complement factor I deficiency.

Authors:  H V Marquart; J M Rasmussen; R G Leslie
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

6.  The molecular basis of hereditary complement factor I deficiency.

Authors:  T J Vyse; B J Morley; I Bartok; E L Theodoridis; K A Davies; A D Webster; M J Walport
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

7.  C3b inactivator deficiency with immune complex manifestations.

Authors:  P Solal-Celigny; M Laviolette; J Hebert; P C Atkins; M Sirois; G Brun; G Lehner-Netsch; J M Delâge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

8.  Correlations between serum factor B and C3b inactivator levels in normal subjects and in patients with infections, nephrosis and hypocomplementaemic glomerulonephritis.

Authors:  J Forristal; K Iitaka; E H Vallota; C D West
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

9.  Complement-dependent histaminase release from human granulocytes.

Authors:  J J Herman; I K Rosner; A E Davis; R S Zeiger; M A Arnaout; H R Colten
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

10.  Metabolism of properdin in normal subjects and patients with renal disease.

Authors:  J B Ziegler; F S Rosen; C A Alper; W Grupe; I H Lepow
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.